2015 American Transplant Congress
Combined Hepatitic/Cholangiopathic Lesion in HIV-HCV Co-Infected Liver Transplant Recipients Associated With Graft Loss
Background: Co-infection with HIV and viral hepatitis results in poorer outcomes following liver transplantation. In this population, complex immune status, extensive drug regimens, and comorbid…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
HCV Treatment in Liver Transplantation: Changes in Center Attitudes and Practices in the DAA Era
Surgery, Johns Hopkins University, Baltimore, MD.
Chronic hepatitis C virus infection (HCV) is the leading indication for liver transplantation (LT) in the US. Safe and effective directly acting antivirals (DAAs) are…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…2015 American Transplant Congress
Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience
Liver Institute, Methodist Dallas Medical Center, Dallas, TX.
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is…2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…
- « Previous Page
- 1
- …
- 26
- 27
- 28